{"nctId":"NCT00936897","briefTitle":"A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates","startDateStruct":{"date":"2009-07"},"conditions":["Postmenopausal Osteoporosis"],"count":833,"armGroups":[{"label":"Ibandronate","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ibandronate"]},{"label":"Denosumab","type":"EXPERIMENTAL","interventionNames":["Drug: Denosumab"]}],"interventions":[{"name":"Ibandronate","otherNames":[]},{"name":"Denosumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ambulatory, postmenopausal women (based on medical history) 55 years or older at screening\n* Postmenopause will be defined as no vaginal bleeding or spotting for at least 12 months\n* If the subject is 55 - 59 years old and there is uncertainty regarding menopausal status, confirmation of serum FSH (\\>= 50 mIU/mL) and serum estradiol (\\<= 20 pg/mL) must be obtained\n* If the subject is 60 years or older, evaluation of FSH and estradiol levels is not needed to confirm menopausal status\n* Have received their first prescription of daily or weekly bisphosphonate therapy at least 1 month prior to screening\n* May have received\n* raloxifene, calcitonin, prior to initiation of daily orweekly bisphosphonate therapy.\n* up to 3 doses of monthly bisphosphonate prior to initiation of daily or weekly bisphosphonate therapy\n* calcium, and vitamin D\n* Hormone replacement therapy (e.g. estrogen use for mitigation of menopausal symptoms)\n* Subject has:\n* Stopped daily or weekly bisphosphonate therapy (is denoted as non-persistent) at least one month before the screening visit, or\n* Demonstrated low adherence to therapy assessed by a score of less than 6 on the OS-MMAS\n* Screening BMD (g/cm2) values, at the lumbar spine OR total hip, that occur within the following ranges, based on the particular scanner that is used:\n\nGE Lunar Lumbar spine 0.700 \\< or = BMD \\< and = 0.940 Total hip 0.504 \\< or = BMD \\< or = 0.756\n\nHologic Lumbar spine 0.607 \\< or = BMD \\< or = 0.827 Total hip 0.454 \\< or = BMD \\< or = 0.698 Both the initial and the repeat DXA scan of the lumbar spine OR the total hip must meet the above eligibility criteria.\n\n* At least 2 lumbar vertebrae must be evaluable by DXA.\n* At least one hip must be evaluable by DXA (eg, no history of either bilateral hip replacement or pins in both hips)\n* Provide signed informed consent before any study-specific procedures are conducted\n\nExclusion Criteria:\n\n* Any disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures\n* Current or prior use of medications prescribed for osteoporosis treatment other than oral daily or weekly bisphosphonate\n* Contraindicated to receive oral ibandronate 150mg PO QM, including\n* Hypersensitivity to ibandronate 150mg PO QM or other constituents of ibandronate 150mg PO QM tablets\n* Abnormalities of the esophagus, which delay esophageal emptying such as stricture or achalasia\n* Inability to stand or sit upright for at least 60 minutes\n* Administration of any of the following treatments within 3 months of screening\n* Tibolone\n* Anabolic steroids or testosterone\n* Glucocorticosteroids (\\>= 5 mg prednisone equivalent per day for more than 10 days or a total cumulative dose of \\>= 50 mg)\n* Vitamin D deficiency \\[25(OH) vitamin D level \\< 20 ng/mL (\\<49.9 nmol/L)\\] - Repletion will be allowed and subjects may be re-screened\n* Evidence of any of the following per subject report, chart review or central laboratory result:\n* Significantly impaired renal function as determined by estimated Glomerular Filtration Rate less that 30mL/min/1.73 m2 determined by the central laboratory\n* Current hypo- or hypercalcemia based on the central laboratory reference ranges\n* Active gastric or duodenal ulcer; or any history of significant gastrointestinal bleed requiring hospitalization or transfusion\n* Known to have tested positive for human immunodeficiency virus, hepatitis C virus, or hepatitis B surface antigen\n* Malignancy (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical or breast ductal carcinoma in situ) within the last 5 years\n* Any metabolic bone disease or secondary cause of bone loss that is not controlled and may interfere with the interpretation of the findings\n* Previous participation in clinical trials with denosumab 60mg SC Q6M (regardless of treatment)\n* Received any solid organ or bone marrow transplant\n* Any laboratory abnormality which, in the opinion of the investigator, will prevent the subject from completing the study or interfere with the interpretation of the study results\n* Known sensitivity to mammalian cell derived drug products\n* Known intolerance to calcium supplements\n* Currently enrolled in or has not yet completed at least 1 month since ending other investigational device or drug trial(s)\n* Any physical or psychiatric disorder which, in the opinion of the investigator, will prevent the subject from completing the study or interfere with the interpretation of the study results\n* Evidence of alcohol or substance-abuse within the last 12 months which the investigator believes would interfere with understanding or completing the study","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"55 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Total Hip Bone Mineral Density Percent Change From Baseline at Month 12","description":null,"paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Type-1 C-Telopeptide Percent Change From Baseline at Month 1","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-81.1","spread":null},{"groupId":"OG001","value":"-35.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12","description":null,"paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12","description":null,"paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null},{"groupId":"OG001","value":"2.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":22,"n":410},"commonTop":["Arthralgia","Upper respiratory tract infection"]}}}